MAPK10

Across TCGA pan-cancer cohorts, MAPK10 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAPK10 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAPK10 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAPK10 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where MAPK10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	1.000	0.286	.049	8	view →
UCEC	DFS	Tertile	II,III,IV	0.263	1.000	.022	8	view →
PDAC	OS	Quartile	All	0.799	0.392	.018	6	view →
LSCC	OS	Median	All	1.000	0.942	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAPK10–CCRCC (OS)

Open the CCRCC breakdown →